Key facts
- Grip Molecular’s last known valuation is $5.0M (Sep 2020).
- It has raised $20.0M.
- Notable investors include gBETA, University of Minnesota Office for Technology Commercialization, EvoNexus, LabCentral, Minnesota Department of Employment and Economic Development — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Grip Molecular
- ·The full record, as it builds
Funding rounds
No funding rounds for Grip Molecular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Grip Molecular
Developer of a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based diagnostic platform designed to provide molecular-level accuracy in infectious disease testing at the point of care or point of need. The company offers proprietary gene-editing chemistry integrated into a lateral flow format, enabling healthcare providers and decentralized testing environments to obtain laboratory-grade sensitivity and specificity in a simple, low-cost format.
- Sector
- Healthcare
- HQ
- Saint Paul, MN, United States
- Founded
- 2019
- Employees
- 7
- Website
- gripmolecular.com/
- Ownership
- Privately Held (backing)
Grip Molecular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grip Molecular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grip Molecular in its N-PORT filings yet. We sweep new filings monthly.